Tezepelumab (TEZ), an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, has demonstrated broad anti-inflammatory effects in severe asthma, including reduced exacerbations and type 2 biomarkers, regardless of the baseline eosinophil level [2]. The gene discussed is TSLP; the disease is asthma.